Perlegen and Bristol-Myers Squibb in Pharmacogenomics Deal

genomeweb
360dx

Perlegen and Bristol-Myers Squibb in Pharmacogenomics Deal

Dec 19, 2002

NEW YORK, Dec. 19-Perlegen Sciences will identify pharmacogenomic markers for Bristol-Myers Squibb, the company said today.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

People in the News: Michael McGarrity, Anthony Schmidt, Jeffrey Alter, More
Expression-Based Survival Signature Proposed for Glioblastoma
Co-Diagnostics Regains Compliance With Nasdaq Listing Requirement
In Brief This Week: HTG Molecular, Lucid Diagnostics, Theradiag, and More
Asthma-Linked Loci Uncovered in Genome-Wide Analysis of Individuals of African Ancestry
New Products Posted to GenomeWeb: Stratec Molecular, Clear Labs, Arrow Diagnostics

The Scan

Better Recovery

A University of California, Los Angeles-led team has found turning off the CCR5 gene could improve recovery after a stroke, according to Scientific American.

Science 'Critical Thinking' Bill in South Dakota

South Dakota lawmakers are to weigh a bill aimed at teaching the strengths and weaknesses of scientific concepts, the Associated Press and KEVN-Black Hills Fox report.

This Week in Science

In Science this week: the synthetic genetic system hachimoji, and more.

No More

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.

Main menu